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Abstract
Coxsackie B viruses types 1–6 (CVB1–6) occur
worldwide and cause a broad spectrum of diseases,
including myocarditis and aseptic meningitis.
Although renal damage due to CVB has been
suspected since the 1950s, these agents are only rarely
searched for in today’s clinical nephrological practice.
Nevertheless, CVB can infect mesangial cells.
Furthermore, infections with these viruses lead to a
histological picture resembling mesangioproliferative
glomerulonephritis and IgA-nephropathy in mice.
In the present article, we provide an overview of
this largely neglected topic, and of the slowly and
steadily increasing evidence suggesting a link between
coxsackieviral infections and kidney diseases.
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Biology of coxsackieviruses
In 1948, while searching for ‘parapoliomyelitis viruses’,
Dalldorf and Sickles [1] discovered a new virus in the
stool of two children who lived in the little town
of Coxsackie, New York. Later, coxsackieviruses were
grouped into two categories—coxsackie A viruses
(CVA, types 1–22 and 24) and coxsackie B viruses
(CVB, types 1–6)—depending on their tissue tropism
and the course of infection in suckling baby mice.
Taxonomically, coxsackie-, polio- and echoviruses
form the genus enteroviridae which belongs to the
family of picornaviridae.
Coxsackieviruses are small (‘pico’) particles with a
diameter of about 30 nm composed of a protein capsid
and an RNA genome [2]. Like other enteroviruses,
they are very resistant to acid and other environmental
inﬂuences. Coxsackieviruses are spread by faecal-oral
transmission and enter the organism via the gastro-
intestinal tract. CVB replicate in enterocytes and
secondarily enter the circulation to affect other organ
systems. As an initial step of infection on the cellular
level, the virus binds to speciﬁc receptors on the surface
of eukaryotic cells. This interaction leads to the release
of viral RNA into the cellular cytoplasm. Here, newly
generated viral RNA-polymerases translate the viral
positive strand (þ) RNA into a complementary minus
() RNA strand, which then serves as a matrix for the
generation of multiple new viral (þ) RNA molecules.
Viral RNA and capsid proteins then assemble to form
complete viruses which are released from the host cell.
Coxsackieviruses do occur worldwide. Most
coxsackieviral infections manifest as a ﬂu-like febrile
disease or remain asymptomatic [2]. However, CVB
in addition cause aseptic meningitis, acute and chronic
myocarditis, paralytic diseases, rhabdomyolysis,
pleurodynia (Bornholm’s disease) and severe septic
diseases in newborns.
Given the fact that the receptors for CVB and the
cellular constituents for replication of CVB have been
identiﬁed in renal tissue [3], it is reasonable to anticipate
that CVB might, at least under certain circumstances,
induce renal damage.
Coxsackieviruses and the kidney
Human case reports
In 1958, 10 years after the discovery of the ﬁrst
coxsackievirus, Utz and Shelokov [4] reported a
generalized CVB3 infection in a 40-year-old male.
During the course of the disease which was character-
ized by biphasic fever, chills, myalgia and headache,
CVB3 was repeatedly isolated from blood, cerebro-
spinal ﬂuid and urine. Renal function, as assessed by
the excretion of phenolsulfonphthalein, was impaired.
On day 5 of the disease state, urinary samples were
positive for CVB, while no virus was detected in the
blood.
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During an endemic of aseptic meningitis in
Japanese children, CVB5 antigen was also detected
within exfoliated urinary cells by immunoﬂuorescence
staining [5].
Besides the detection of CVB in urine, the virus
was identiﬁed in renal tissue exhibiting evidence for
an inﬂammatory reaction. Burch and Colcolough [6]
identiﬁed abundant CVB4 antigen in myocardial
and renal tissue of a 45-year-old male who had died
of pancarditis and nephritis. Interstitial inﬂam-
mation and areas of focal chronic glomerulonephritis
with increased cellularity of the glomerular tufts,
crescent formation, and hyalinization of the glomeruli
were encountered. Similarly, Benyesh-Melnick et al. [7]
isolated CVB1 from kidney tissue of a child dying
from myocarditis.
Later on, CVB4 glomerulonephritis characterized
by viruria, proteinuria, haematuria, leukocyturia, high
blood pressure and an elevated blood urea nitrogen in a
9-year-old boy was published by Bayatpour et al. [8].
Burch et al. found CVB4 by immunoﬂuorescence in the
kidney of a 19-year-old male who had died from acute
dilated cardiomyopathy [9]. Furthermore, Aronson and
Phillips [10] reported six adult patients with
acute oliguric renal failure who concurrently showed
a signiﬁcant rise of CVB5 antibody titre levels. In a
systematic autopsy study, CVB antigen was detected
by immunoﬂuorescence staining in the kidneys of
11 out of 104 unselected patients [11]. The speciﬁc
viral antigen–antibody reaction displayed focal, bright
intracytoplasmatic ﬂuorescence scattered within the
glomerulus, tubular epithelium and interstitial tissue.
In a study focusing viral infections in renal transplant
recipients, CVB3 was isolated from two of 20 urine
samples [12]. Unfortunately, no information was given
about the clinical status and the kidney function of
the affected patients. Furthermore, four patients with
renal transplant rejection in the presence of sharply
rising CVB4 antibody titres and clinical features of
coxsackieviral infection and renal failure have been
identiﬁed [13].
The restricted number of cases linking CVB infection
with renal disease was reported before 1976. At that
time, genetic identiﬁcation of viruses by modern
technology was not available. The analysis of the
patients’ histories does not allow a ﬁrm conclusion as
to whether the CVB virus was directly responsible for
the impaired renal function. Therefore, investigations
in animals might possibly be more informative.
Animal studies
Sun et al. [14] described a consistent sequential
pattern of the histologic renal lesions induced by
CVB1 in mice. Two weeks after infection, glomeruli
showed increased cellularity with proliferation and
swelling of endothelial and mesangial cells. Later,
fusion of capillary loops led to a picture similar to
lobular glomerulonephritis. More advanced lesions
showed sclerosing changes of the glomeruli and partial
or complete hyalinization of the glomerular tuft.
Fluorescence microscopy exhibited deposition of
gamma-globulin along capillaries in irregular clumping
patterns. These observations corroborated publications
from the 1950s and 1960s showing histological changes
and excretion of CVB1 [15] and CVB5 [16] in the urine
of infected mice.
Kamiyama [17] developed a more chronic model
and inoculated mice with CVB4 administered once
a month for 9 months. He reported mesangial cell
proliferation, marked changes of the glomerular
basement membrane, crescent formation, interstitial
inﬂammation and equal amounts of IgA and IgG
deposits in the glomeruli.
Yoshida et al. observed by in-situ hybridization
strong CVB4-speciﬁc positive strand (þ) RNA signals
in mesangial cells [18]. In their model, CVB4
were inoculated monthly into mice for 5 months.
Interestingly, predominant glomerular IgA depositions
along with mesangial proliferation were detected
for several months after infection (Figure 1), suggesting
a kind of experimental IgA-nephropathy.
In order to establish whether mesangial cell function
was disturbed by CVB4 infection, Kume [19] studied
the clearing of colloidal carbon by mesangial cells
in CVB4-infected mice and found a reduced clearance
in infected when compared with non-infected animals.
The histological changes observed in mice were
corroborated by ﬁndings in other species. Burch
et al. [20] infected squirrel monkeys with CVB4,
and observed a marked proliferation of mesangial
and endothelial cells. The lesions were patchy in
distribution. Virus could be isolated from renal
tissue in two monkeys necropsied 3 and 7 days after
inoculation.
Thus, contrary to human investigations, the studies
in mice and monkeys deﬁnitely indicate a pathogenic
potential, at least following inoculation of high
amounts of CVB1 and CVB4. The lesions appear
to be predominantly glomerular and reminiscent of
human IgA nephropathy.
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Fig. 1. Intensity of glomerular IgA by immunoﬂuorescence in
CVB4-infected mice. Bar height represents mean for infected mice
(hatched) and control mice (open). Intensity was graded on a scale
where negative¼ 0, slight¼ 0.5, mild¼ 1, moderate¼ 2 and
marked¼ 3 (adapted from [18]).
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In-vitro studies
Conaldi et al. [3] generated primary kidney cell lines
from the unaffected part of human kidneys resected
because of a carcinoma. The resulting cell lines of
proximal tubular epithelial cells, glomerular podocytes
and glomerular mesangial cells were inoculated with
reference strains of CVB1–6. Mesangial cells expressed
smaller amounts of CVB receptors than proximal
tubular epithelial cells. After infection, all cell lines
produced viable viruses. A cytopathic effect was
observed with glomerular epithelial cells and proximal
tubular epithelial cells only. In contrast, mesangial
cells survived and even established a state of persistent
infection. This chronic carrier-state was most
pronounced with CVB1, 3 and 5 which were produced
in high and stable titres for at least 50 days (Figure 2).
Phagocytic function of mesangial cells was tested
by phagocytosis assays with IgG-coated latex beads
and was dramatically reduced in infected cells.
Also, contractility of mesangial cells was diminished
signiﬁcantly.
Based on these investigations one might predict
that ﬁrst, the renal lesions induced by CVB will be
mixed glomerular and tubular, and second, the
nephrotoxic potential depends on the strain of CVB
virus causing the infection.
Comments and outlook
From the data presented, it is likely that CVB can
infect kidney cells in vivo and in vitro, and in doing so
induce transient or chronic kidney diseases.
CVB leads to cytopathic effects in renal tissue.
When primary cell cultures of human podocytes and
proximal tubular epithelial cells are infected with
CVB1–6, they show cytopathic effects and lysis of the
infected cells [3]. In vitro, lytic infections lead to
the release of high titres of CVB and to the shedding
of adherent cells from the plastic material. Against this
background, one is tempted to speculate that a similar
mechanism explains transient viruria and shedding
of virus-bearing cells from the urinary tract during
CVB infection.
The interaction between CVB and mesangial
cells depends on the subtype of CVB. In vitro, human
primary mesangial cell cultures are infectable with
CVB1–6 [3]. CVB1, 3 and 5, cause a persistent and
ongoing infection and a continuous production of
virus. Interestingly, CVB1, 3 and 5, but not CVB2,
4 and 6, bind to decay accelerating factor (DAF/CD55)
which is a glycosylphosphatidylinositol-anchored
cell surface protein consisting of ﬁve extracellular
short consensus repeats [21,22]. Whether differential
binding to DAF/CD55 simply reﬂects coincidence or
DAF plays a role in the induction of carrier-states of
CVB-infected cells, remains to be established.
The presence of CVB in mesangial cells seems to be
functionally relevant, since persistent in vitro infection
of mesangial cells leads to impaired phagocytosis
and thereby to an impaired clearing function of these
cells [3]. Furthermore, cellular contractility, another
important property in glomerular pathophysiology,
is markedly reduced in chronically CVB-infected
mesangial cells. In accordance with these ﬁndings,
inoculation of CVB4 causes delayed mesangial
clearance of colloidal carbon in mice [19].
When CVB4 are injected into mice, a mesangio-
proliferative glomerulonephritis with histologically
variable expression develops. In some studies, increased
mesangial cellularity was only transiently found
[17,23–25], whereas in others the effect lasted for
many months [18,26]. These differences are best
explained by different routes, frequencies and amounts
of CVB applied, and by the different strains of viruses
and mice used. Whether the experimental ﬁndings
explain, at least in part, the heterogenous clinical course
of coxsackieviral infections encountered in humans
awaits clariﬁcation. With respect to chronic infection of
cells in vivo, viral antigen and viral positive strand (þ)
RNA have been detected by immunoﬂuorescence
and by in-situ hybridization in murine kidneys [3,25].
This indicates a replication of CVB in these cells.
The pathophysiologic mechanism by which kidney
damage is induced in CVB infection is not known.
It has been suggested that acute damage is caused by
acute and lytic infection of cells. In contrast, chronic
damage might be induced by chronic infection of cells
followed by consecutive immune-complex-related
mechanisms of glomerular injury [14,27]. The latter
mechanism could explain the interesting observation
of CVB4-induced IgA-nephropathy [18].
Tropism towards different tissues and organs
has been a long known feature of different CVB strains.
As an example, CVB3 strains inducing fulminant
myocarditis in mice have been described as well as
strains which do not affect the murine heart at all
[28,29]. Although the reason for this phenomenon has
not been elucidated in detail, in analogy to cardiotro-
pism, different CVB strains might exhibit different
degrees of nephrotropism. If this was the case,
many wild type CVBs might cause simply transient or
0
1
2
3
4
5
6
7
0 10 20 30 40 50
Days after infection
Vi
ru
s 
tit
re
 (lo
g T
CI
D5
0/m
l)
CVB5
CVB3
CVB1
CVB4
CVB2
CVB6
Fig. 2. Viral titres during infection of mesangial cells in vitro.
CVB1, 3 and 5 induce a chronic and persistent infection in human
primary mesangial cell culture. In contrast, CVB2 and 6 are cleared
from the cells in 30–40 days. CVB4 produces a prolonged infection
with slowly declining viral titres (adapted from [3]).
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no signiﬁcant kidney damage at all. On the other hand,
more nephrotropic strains might induce acute or
chronic functional impairment of renal function.
In this context, immunosuppression or previous
kidney damage could be the factors rendering the
kidney more vulnerable towards infections with
coxsackieviruses. In accordance with this possibility,
CVB-induced transplantation kidney failure has been
described [13].
The causes of most of the glomerular and interstitial
types of nephritis remain unknown. Given the human
case reports, the acute and chronic experimental
inﬂammatory kidney diseases induced by CVB and
the observations in cell cultures derived from kidney
cells, it is reasonable to assume that CVB are clinically
relevant for renal disease and should be investigated
accordingly in the future.
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